



#NANSRFS: VISUAL ABSTRACT SERIES

IDDS VS. CMM FOR REFRACTORY CANCER PAIN

STUDY POPULATION



N = 200

Prospective, Randomized, Multi-center

INTERVENTION



VS.



101 patients underwent IDDS
4 week follow up, n= 73

99 patients had CMM
4 week follow up, n=75

REDUCTION
IN VAS
SCORES

IDDS= 51.5%
CMM = 39%



PAIN

TOXICITY

REDUCTION
IN TOXICITY

IDDS= 50.3%
CMM= 17%



IMPROVED
SURVIVAL

IDDS= 53.9%
CMM = 37.2%



SURVIVAL

CMM + IDDS > CMM ALONE IN REDUCING PAIN & TOXICITY AND INCREASING SURVIVAL



BROUGHT TO
YOU BY
#NANSRFS



Smith et al. Journal of Clinical Oncology Oct, 2002
www.ncbi.nlm.nih.gov/pubmed/12351602